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Abstract 
Diabetic ketoacidosis is a rare but serious and life-threatening acute 
complication of diabetes mellitus. It is characterized by ketoacidosis with 
other findings and should be treated immediately. In this case, a 33-year-old 
diabetic patient who admitted to the emergency department with diabetic 
ketoacidosis is presented. The patient was prescribed empagliflozin (sodium 
glucose cotransporter inhibitor-2) a month ago. The SGLT-2 inhibitors have 
been approved for use in the treatment of type 2 DM and are still not used in 
the treatment of type 1 DM. There are such reports of unusual side effects 
related SGLT-2 inhibitors, in the literature and among them, ketoacidosis is 
a rare and important side effect.
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Introduction 
Diabetic ketoacidosis (DKA) is a serious and life-threatening acute 
complication of diabetes mellitus. It is characterized by ketoacidosis and 
hyperglycemia. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors 
decrease plasma glucose levels by blocking the reabsorption of glucose from 
the proximal tubules (Zinman B et al., 2015). SGLT-2 inhibitors are indicated 
as an add-on therapy when a single agent is inadequate to achieve glycemic 
goals in type 2 DM. Several studies have shown beneficial glycemic effects of 
SGLT-2 inhibitors in selected type 1 DM patients. (Plosker GL.2014,Sha S et 
al. 2011). However, regulatory agencies (as FDA) have not approved this class 
of drugs for type 1 diabetic patients, yet. Some case reports suggest that SGLT-
2 inhibitors may be attributed to an increased risk of diabetic ketoacidosis 
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(Ogawa W et al., 2016). We aimed to emphasize diabetic ketoacidosis as a 
rare potential complication of Empagliflozin treatment. In this case, we 
present a patient who developed diabetic ketoacidosis after using SGLT-2 
inhibitor. 
 
Case 
A 33-years-old female patient admitted to our hospital with nausea, 
vomiting and mild abdominal pain for the past 2 days. She was diagnosed in 
an another health center with insulin dependent diabetes mellitus (DM) 4 years 
ago and had mental retardation. Patient’s oral intake was inordinate due to 
mental retardation. The patient had no fever, alcohol intake history, smoking 
or surgical intervention history. As her symptoms became worse, she applied 
to the emergency clinic of our hospital. She was treated with Insulin Glargine 
and Insulin Glulisine for 4 years. Empagliflozin treatment (10 mg per day) was 
started one month ago. Vital signs at the time of admission were as follows; 
temperature 36.3 °C, pulse rate 120 beats/min, respiratory rate 28  breaths/min 
and blood pressure 153/89  mm Hg. The patient was dehydrated with sunken 
eyes, dry oral mucosa and poor skin turgor. The patient had thoraco-abdominal 
pattern of breathing. Auscultation of the lungs revealed no significant findings. 
Arterial blood gases showed severe metabolic acidosis with an elevated anion 
gap (pH 7.04, CO2 16.8  mmHg, HCO3 6.2 mEq/L, anion gap  28.1 mEq/L). 
Hyperglicemia (419 mg/dL), ketonuria and glucosuria were also detected. 
Serum lactate level was normal (1.55 mg/dL). Coagulation parameters (INR, 
prothrombin time), liver enzymes, renal functions, serum protein, albumin and 
other laboratory findings were normal. Chest radiogram and 
electrocardiogram showed no significant findings. She was hospitalised in the 
intensive care unit with diabetic ketoacidosis. The patient was rehydrated with 
intravenous fluid solutions and electrolyte replacement was given. The 
patient's Empagliflozin treatment was discontinued. Serial arterial blood gas 
analyses showed an apperent improvement on ketoacidosis after the treatment. 
The follow up is being continued in our clinic.  
 
Discussion 
DKA is characteristically associated with type 1 diabetes. It also 
occurs in type 2 diabetes under conditions of extreme stress such as serious 
infection, trauma, cardiovascular or other emergencies and less often, as a 
presenting manifestation of type 2 diabetes. The most widely used diagnostic 
criteria for diabetic ketoacidosis include blood glucose >250 mg/dL, arterial 
pH <7.3, serum bicarbonate <15 mEq/L and a moderate degree of ketonemia 
and/or ketonuria (Kitabchi et al, 2001). DKA is more common in younger (<65 
years) patients (Benoit et al, 2018). Empagliflozin is a selective SGLT-2 
inhibitor which can be used either as a single treatment or in combination with 
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other antidiabetics. It is approved by the FDA (U.S. Food and Drug 
Administration) in 2014 for type 2 diabetic patients.. This drug increases the 
amount of glucose excreted in urine and beneficial for lowering the blood 
glucose level. It provides a reduction in required insulin doses for type 2 
diabetic patients. SGLT-2 inhibitors that are given with insulin control 
hyperglycemia in type 2 diabetes mellitus without increasing the risk of 
hypoglycemia. 
It was found that SGLT-2 inhibitors cause an increase in urinary tract 
infection, bladder cancer, acute renal failure, bone fracture and diabetic 
ketoacidosis frequencies (Musso et al, 2012). Also, in some of the diabetic 
patients using SGLT-2 inhibitor, an increase in the incidence of euglycemic 
diabetic ketoacidosis was observed (Taylor et al, 2018). Since 2015, several 
cases of DKA associated with SGLT-2 inhibitors were reported both in type 1 
DM and type 2 DM (Taylor et al, 2018-Rosenstock J. et al, 2015). Type 1 DM 
patients who treated with SGLT-2 inhibitors could achieve glucose regulation 
but ketoacidosis frequency increases in this patients. SGLT2 inhibitors 
enhance risk of ketogenesis and lead to DKA, especially in susceptible 
diabetic patients and in the presence of precipitating factors (Fattah, H.et al, 
2018). Insulin-independent glucose clearance, hyperglycaemia, and volum 
deficiency are implicated as mechanisms (Peters et al, 2015). As seen in our 
case, patients using SGLT-2 inhibitors who have nausea, vomiting, and 
reduced oral intake should be carefully examined for diabetic ketoacidosis. 
The use of SGLT-2 inhibitors in patients with type 1 diabetes is considered to 
be non-indicative and is not suitable for use in these patients. Experiences with 
Empagliflozin associated DKA are still limited. There are still no sufficient 
data on this subject and further clinical studies are needed (Ahmed-Sarwar et 
al, 2017). 
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